ECElvio Covino

Elvio Covino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elvio Covino has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites

    by Emanuela Salvatorelli, Pierantonio Menna, Massimo Chello, Elvio Covino, Giorgio Minotti

    Cumulative doses of doxorubicin and other antitumor anthracyclines may cause heart failure (HF). Cardiotoxicity is determined by cardiac exposure to anthracyclines and to more toxic secondary alcohol metabolites that are formed inside cardiomyocytes or diffuse from the bloodstream. Concerns exist that HF might be caused by cumulative anthracycline doses that were thought to be safe. Patients with gain-of-function polymorphism of carbonyl reductase 3 (CBR3), which converts anthracyclines to secondary alcohol metabolites, would be at a higher risk of HF. Recently a pharmacokinetic model was developed that simulated clinical exposure of human myocardium to anthracyclines and incorporated simulations of CBR3 polymorphism. It was shown that HF risk could occur after lower doxorubicin doses than previously reported, particularly for patients with CBR3 polymorphism (Salvatorelli et al., J. Pharmacol. Exp. Ther. 362:263-270, 2017). Here we show that also daunorubicin and idarubicin, but not epirubicin, might cause HF after reportedly safe cumulative doses. CBR3 polymorphism increased HF risk from daunorubicin and idarubicin to a greater extent as compared to doxorubicin. This was caused by daunorubicin and idarubicin forming higher levels of toxic metabolites in human myocardium; moreover, daunorubicin and idarubicin metabolites diffused from plasma and accumulated in cardiac tissue, while doxorubicin metabolite did not. CBR3 polymorphism did not aggravate HF risk from epirubicin, which was caused by the very low levels of formation of its toxic metabolite. These results support concerns about HF risk from low dose anthracycline, characterize the analog specificity of HF risk, and illuminate the role of secondary alcohol metabolites.


  • Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting

    by Antonio Nenna, Mario Lusini, Cristiano Spadaccio, Francesco Nappi, Filippo Prestipino, Raffaele Barbato, Adele Casacalenda, Giuseppe Pugliese, Filippo Barberi, Omar Giacinto, et al.

    Aims Statins are a widely recognized weapon in the primary and secondary prevention of coronary artery disease for their pleiotropic effects. However, recent reports from the cerebrovascular and pharmacological literature are insinuating concerns about a potential increase in the haemorrhagic risk among statin users. The effect of statins in postoperative bleeding should be carefully investigated in major cardiac surgery that exposes per se to risk of bleeding. Methods In this retrospective cohort study, we evaluated 441 patients who received atorvastatin until surgery and 213 patients who had never been treated with statins, undergoing elective primary isolated on-pump coronary artery bypass grafting. Postoperative bleedings, blood products use and complications were monitored during hospitalization. Results Preoperative and intraoperative variables were similar between groups. Early and overall postoperative bleedings were reduced among statin users, who had lower C-reactive protein values in the first postoperative day. Atorvastatin carries a strong protective effect against major bleedings, with a propensity score-adjusted odds ratio of 0.28 (P < 0.01). Also, blood products use for statin-treated patients was lower compared with controls, with fewer transfused patients and fewer red-packed cells units per transfused patient. Conclusion Preoperative atorvastatin use is associated with reduced risk of bleeding and blood products use after coronary artery bypass grafting, likely due to a reduction in the postoperative inflammatory response. Statin continuation at the highest tolerable dose should be encouraged before cardiac surgery. The preoperative use of statins in cardiac surgery as ‘bleeding-preventers’ might have profound clinical implications.


  • Open Access

    Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin

    by Emanuela Salvatorelli, Pierantonio Menna, Massimo Chello, Elvio Covino, Giorgio Minotti

    The antitumor anthracycline, doxorubicin (DOX), can cause heart failure (HF) upon cumulative administration. Lowering the cumulative dose of DOX proved useful to minimize HF risk, and, yet, there is a growing concern that HF might occur after doses that were thought to be safe. Clinical trials that prospectively address such concerns are lacking. Because HF risk correlates with cardiac exposure to DOX, cumulative doses associated with HF risk were re-explored by modeling the accumulation of anthracycline pools in human myocardium. Ex vivo myocardial samples were used in vitro to simulate DOX rapid infusions. The accumulation of anthracycline pools was measured and incorporated into equations from which a risk versus dose curve was obtained. The experimental curve identified a 5% risk dose that was congruent with a previously reported clinical value (380 versus 400 mg/m2, respectively); however, 1–2% risk occurred after lower doses than reported. Simulations of gain-of-function polymorphism of carbonyl reductase 3, which converts DOX to its poorly diffusible alcohol metabolite, doxorubicinol (DOXOL), expanded anthracycline pools and caused 5% or 1–2% risk doses to decrease to 330 or 180–230 mg DOX/m2, respectively. These data show there is no safe dose of DOX. Diminishing cardiac exposure to circulating DOX may represent a cardioprotective strategy. We show that DOX slow infusions or liposomal DOX, which reduce cardiac exposure to DOX, caused formation of smaller anthracycline pools, did not generate DOXOL, increased the 5% risk dose to 750–800 mg/m2, and prevented HF risk aggravation by carbonyl reductase polymorphism.


  • Papillary Muscle Approximation Versus Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation

    by Francesco Nappi, Mario Lusini, Cristiano Spadaccio, Antonio Nenna, Elvio Covino, Christophe Acar, Massimo Chello


  • The concomitant management of cancer therapy and cardiac therapy

    by Emanuela Salvatorelli, Pierantonio Menna, Emilia Cantalupo, Massimo Chello, Elvio Covino, Federica I. Wolf, Giorgio Minotti


  • Electrical Modeling of an Isolated Surgical Aortic Valve Replacement for Microshock Risk Assessment

    by Emanuele Zennaro, Elvio Covino, Carlo Mazzetti di Pietralata, Fabio Fiamingo, Giovanni Luca Amicucci

    This paper deals with the method and the concepts to obtain the circuit of the surgical layout and provides the most critical values of leakage current flowing through the heart of the patient during the phases of a surgical intervention. Different fault conditions to the operating room power supply system and to the involved electrical medical equipment are simulated. The obtained currents are compared with the values experimented by the recent investigations on electrical current inducing ventricular fibrillation (VF). The risk estimation is obtained by the product of the probability of VF when certain fault conditions occur and the probability of occurrence of the considered fault conditions. This in-depth investigation of the microshock probability provides the knowledge necessary to adopt suitable protection measures, additional to those already implemented for risk reduction.

  • Open Access

    Staged transthoracic approach to persistent atrial fibrillation (TOP-AF): study protocol for a randomized trial

    by Claudio Pragliola, Pasquale Mastroroberto, Mario Gaudino, Massimo Chello, Elvio Covino

    Persistent atrial fibrillation frequently shows multiple different electrophysiological mechanisms of induction. This heterogeneity causes a low success rate of single procedures of ablation and a high incidence of recurrence. Surgical ablation through bilateral thoracotomy demonstrates better results after a single procedure. Prospective observational studies in inhomogeneous populations without control groups report a remarkable 90% of success with hybrid or staged procedures of surgical ablation coupled with catheter ablation. In this trial, we will examine the hypothesis that a staged approach involving initial minimally invasive surgical ablation of persistent atrial fibrillation, followed by a second percutaneous procedure in case of recurrence, has a higher success rate than repeated percutaneous procedures.


  • Simvastatin attenuates the endothelial pro-thrombotic shift in saphenous vein grafts induced by Advanced glycation endproducts

    by Cristiano Spadaccio, Federico De Marco, Fabio Di Domenico, Raffaella Coccia, Mario Lusini, Raffaele Barbato, Elvio Covino, Massimo Chello


  • Long-term results of an open flexible prosthetic band for mitral insufficiency

    by Claudio Pragliola, Massimo Chello, Mario Gaudino, Andrea Mazza, Carlo Cellini, Cristiano Spadaccio, Elvio Covino

    Background: use of a prosthetic ring is an integral part of any mitral valve repair and can influence the long-term stability of the results. We evaluated the long-term results of the AnnuloFlex ring implanted as an open flexible band in patients affected by degenerative mitral disease. Methods: between 2001 and 2010, 82 patients (52 women, 30 men) with a mean age of 62 years, underwent repair of a prolapsing mitral valve with an AnnuloFlex band. One patient was reoperated on for a technical error and received a mechanical prosthesis, 3 were missing at follow-up, and the other 78 were prospectively followed up with clinical interviews and transthoracic echocardiography. Results: the mean follow-up was 7.0 ± 1.8 years. Six patients died; 2 deaths were considered valve-related. The overall survival estimate at 10 years was 88.6% (95% confidence interval: 76.1%–94.8%). Freedom from endocarditis was 97.1% (95% confidence interval: 89.1%–98.5%). Freedom from thrombosis or hemorrhage was 93.7% (95% confidence interval: 81.6%–97.9%). Freedom from new or increased regurgitation was 93.1% (95% confidence interval: 87.3%–97.3%). The cumulative freedom from any valve-related event was 78.6% (95% confidence interval: 69.7%–97.1%). A single case of systolic anterior motion occurred before hospital discharge. Conclusion: the long-term results of the AnnuloFlex band are excellent and stable.

  • Atrial natriuretic peptide property on the ischemic myocardium inducing HSP72

    by Silvio Olivito, Massimo Chello, Elvio Covino, Pasquale Mastroroberto

    Background: the purpose of this study was to investigate the effectiveness of atrial natriuretic peptide on ischemic myocardium through the induction of heat-shock protein 72. Methods: 30 isolated rabbit hearts perfused on isolated heart apparatus were randomly assigned to receive either warm Krebs-Henseleit solution with 1 µmol L −1 atrial natriuretic peptide ( n = 15) or warm Krebs-Henseleit solution without atrial natriuretic peptide ( n = 15) in preischemic, ischemic, and postischemic conditions. In all rabbit hearts, global ischemia was produced by clamping the aortic and atrial inflow lines. Concentrations of atrial natriuretic peptide were measured in hearts with left ventricular dysfunction following ischemia, and correlated with the hypertrophic growth sustained by overexpression of heat-shock protein 72 microRNA-133. Results: the levels of atrial natriuretic peptide were markedly higher in the group that received atrial natriuretic peptide, and strongly correlated with both band lengths of heat-shock protein 72 and overexpression of microRNA-133 in the hypertrophic myocyte. Conclusions: perfusion levels of atrial natriuretic peptide induce increased expression of heat-shock protein 72 microRNA-133 in dysfunctional left ventricle.